about
Dexamethasone intravitreal implant in the treatment of diabetic macular edemaNanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug deliveryInfluence of lipophilicity on drug partitioning into sclera, choroid-retinal pigment epithelium, retina, trabecular meshwork, and optic nerveIntrascleral drug delivery to the eye using hollow microneedles.Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR)Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow.Topical, Aqueous, Clear Cyclosporine Formulation Design for Anterior and Posterior Ocular Delivery.The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease.Modeling of corneal and retinal pharmacokinetics after periocular drug administrationEffect of eye pigmentation on transscleral drug delivery.Sustained release micellar carrier systems for iontophoretic transport of dexamethasone across human sclera.Periocular routes for retinal drug delivery.Evaluation of the intravenous and topical routes for ocular delivery of hesperidin and hesperetin.Sustained transscleral drug delivery.Topical WIN55212-2 alleviates intraocular hypertension in rats through a CB1 receptor mediated mechanism of actionInfluence of drug lipophilicity on drug release from sclera after iontophoretic delivery of mixed micellar carrier system to human sclera.Pharmacokinetic Studies of Sustained-Release Depot of Dexamethasone in Beagle DogsEffects of antiglaucoma drugs on blood flow of optic nerve heads and related structures.Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.Advances in the understanding of retinal drug disposition and the role of blood-ocular barrier transporters.Ophthalmic drug delivery in glaucoma-a review.Neurotrophin family members as neuroprotectants in retinal degenerations.Hydrophilic prodrug approach for reduced pigment binding and enhanced transscleral retinal delivery of celecoxib.Iontophoretic transport of charged macromolecules across human sclera.Suprachoroidal delivery in a rabbit ex vivo eye model: influence of drug properties, regional differences in delivery, and comparison with intravitreal and intracameral routes.Probenecid treatment enhances retinal and brain delivery of N-4-benzoylaminophenylsulfonylglycine: an anionic aldose reductase inhibitor.Effect of diclofenac on ocular levels of ciprofloxacin and lomefloxacin in rabbits with endophthalmitis.Principles of pharmacology in the eye.Clozapine directly relaxes bovine retinal arteries.Alternative Drug Delivery for Patients Undergoing Cataract Surgery as Demonstrated in a Canine Model.Systemic and periocular deliveries of plasminogen kringle 5 reduce vascular leakage in rat models of oxygen-induced retinopathy and diabetes.Ocular Nerve Growth Factor (NGF) and NGF Eye Drop Application as Paradigms to Investigate NGF Neuroprotective and Reparative Actions.Hydrogel Ring for Topical Drug Delivery to the Ocular Posterior Segment.Insights into gold nanoparticles as a mucoadhesive system
P2860
Q26799423-0085985D-CAB3-4A58-AAFA-4DAE0592936AQ27007119-758B76B5-CB06-41F6-A84A-D714A83AFA24Q33714957-53F73922-63B4-4F2A-A3E8-5A644F6E3148Q33978350-DA53813A-C19B-42EF-97CB-85692B8ED9A0Q34701929-B0FBBC4E-8975-437A-B7E7-068FC456B5E9Q34735196-E42F27F9-354B-40AC-8455-ACF59D20284DQ35187905-763EED79-9174-47F9-9475-52CE3ACBD310Q35565484-9C97C30B-22AD-4DEB-9939-1D322AF246E1Q35807878-83F505E9-E934-4FEF-8CAE-83B761231CD2Q35882664-AC01C9A2-B2FD-40ED-81D5-394C9194EBCEQ35884964-98FCD2CA-1754-4EA9-A78C-7BFB76A332C6Q36024067-BA6A8586-5A1C-4197-8EF5-E6171E3612BBQ36316631-B5BD4819-D117-4E17-9AEE-398304C54C84Q36421799-DB273F5F-14F9-40DE-8729-4869952934E9Q37039016-EFE5F0D9-4CA2-48C1-8689-018677ADDE63Q37086961-68511EFA-1958-4B67-96F5-390F4E7A21EBQ37274226-EDF6909E-432B-48D8-9EDC-B64DEF3E712EQ37409001-C5EC038A-BBA5-4511-8A5F-A4D633C88C07Q38074311-FA369324-71C9-4E45-89DE-6831C7927161Q38100561-277E10D3-EA69-4E1E-9EE2-DDBAF8D7D945Q38104396-42B88C9A-473E-49F3-B609-EB62D1BDFA70Q38168357-D0453CB5-3DA7-454F-9DA3-BB34536C5D83Q38269424-E2A439D6-C5CC-4188-AAAA-65002B794B1FQ39410312-86C4E4BA-C3D9-4244-84E5-DB8065DF1609Q39623649-9A257E62-D142-4C72-92EC-EAED42976A89Q41344810-7AE43FE3-B7D6-4D28-A3DE-2DC7164A0717Q42031044-8300882C-3772-42C4-88A7-2E99E3217F1DQ44907582-F6AE77EF-4857-4562-9C41-99205BEBBDCCQ45871474-D86C26CB-1B4B-49B7-880C-C51DB6F058C0Q46425631-4F1C245B-8166-4BD2-8D80-BE673BAED851Q46545095-57DEC679-7712-4093-84B5-96C6642F9427Q46658213-B317D980-9144-4035-A1F0-B6DA862C0CBAQ47339159-CCA9BC3A-37D0-4656-B202-E9BDEC235772Q51823268-22801C16-E8DA-46FA-945C-8EAF309BE098Q58698711-09CDF865-B6E2-4B91-9E84-67C6B09C5BE0
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Drug delivery to the posterior segment from drops.
@ast
Drug delivery to the posterior segment from drops.
@en
Drug delivery to the posterior segment from drops.
@nl
type
label
Drug delivery to the posterior segment from drops.
@ast
Drug delivery to the posterior segment from drops.
@en
Drug delivery to the posterior segment from drops.
@nl
prefLabel
Drug delivery to the posterior segment from drops.
@ast
Drug delivery to the posterior segment from drops.
@en
Drug delivery to the posterior segment from drops.
@nl
P1476
Drug delivery to the posterior segment from drops.
@en
P2093
David M Maurice
P304
P356
10.1016/S0039-6257(02)00326-0
P478
47 Suppl 1
P577
2002-08-01T00:00:00Z